Gemcitabine, Oxaliplatin and Paclitaxel (GemPOx ) in Patients with Relapsed or Refractory Germ Cell Tumors After High Dose Chemotherapy, A Retrospective Single-Center Experience

Creative Commons License

Acar R., Erturk I., Kiziloz H., Okcelik S., Yildiz B., Aykan M. B., ...Daha Fazla

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.30, sa.4, ss.191-196, 2020 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4999/uhod.204657
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.191-196
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Germ cell tumors are chemosensitive tumors, and patients with metastatic germ cell tumors can be cured even in the metastatic setting. There are limited treatment options for the patients who have refractory or recurrent disease after high dose chemotherapy (HDCT) with autologous stem cell transplantation. We aimed to show real-life data on health outcomes in adult patients with recurrent or refractory germ cell tumor who received the gemcitabine, oxaliplatin, and paclitaxel (GemPOx) combination regimen.We analyzed the data of 33 patients receiving GemPOx regimen after HDCT in our department between January 2016 and January 2020. Primary objectives were overall response rate (ORR), overall survival (OS), and progression-free survival (PFS). The mean age of the study group was 31.5 +/- 8.2 years. Of the 33 patients, 27 (81.8%) were men. The median OS and PFS were 16 months (95% CI: 7.33-24.7) and 10 months (95% CI: 5.1-14.9), respectively. The one-year OS and PFS were 65.7% and 40%, respectively. ORR was 42.4%. Toxicity was managable.Our study demonstrates acceptable safety and efficacy of GemPOx regimen for relapsed refractory patients with germ cell tumors. GemPOx remains one of the best determined systemic treatment options for progressive germ cell tumors patients after HDCT.